OptimizeRx Q3 2026: Revenue Down But Profits Rise on Strong EBITDA Margins
OptimizeRx reported Q3 2026 revenue of $21.6M and adjusted EBITDA of $6.3M, significantly beating consensus. The company updated fiscal year 2026 revenue guidance to $87M-$93M, citing year-over-year contract declines offsetting RFP momentum. Debt reduction also continued.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed